An Overview and Discussion of Azido Impurities and their Risk Assessments in Drug Substances and Drug Products
Asian Journal of Applied Chemistry Research · pp. 20–30 · Published 30 May 2023
10.9734/ajacr/2023/v13i4251Abstract
Azido impurities are known to be mutagenic and carcinogenic. A small exposure to these impurities may lead to cancer. These impurities may be formed and get incorporated into drug substances or drug products through reagents, catalysts, solvents, or raw materials used in the process of manufacturing drug substances. Various regulatory authorities have published press releases and notices regarding the control of these impurities with the interim limit. Azido impurities can be avoided by taking precautions during the manufacturing of drug substances and products. The methods used to identify and quantify these impurities require highly sensitive instruments such as LCMS/MS or GCMS, which can detect these impurities to a trace level within the given interim limit. These methods are validated according to various regulatory guidelines. Liquid chromatography, along with a mass detector, is mostly used for their determination.
References (10)
- 1 Azides: their preparation and synthetic uses [DOI]
- 2 Mutation research/fundamental and molecular mechanisms of mutagenesis [DOI]
- 3 Analytical Method Validation and Instrument Performance Verification [DOI]
- 4 Analytical Techniques in the Pharmaceutical Sciences [DOI]
- 5 Electrophilic Azides for Materials Synthesis and Chemical Biology [DOI]
- 6 Click Reactions in Organic Synthesis [DOI]
- 7 Metabolic activation of the mutagen azide in biological systems [DOI]
- 8 Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines [DOI]
- 9 Development and validation of an LC-MS/MS method for simultaneous determination of three organic azido impurities in tetrazole-containing sartans [DOI]
- 10 ICH M7 – Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk [DOI]
Cited by 23
Aigerim Zhaxybayeva, Khava Yevloyeva, Saltanat Kaliyeva, Nurgul Nurmukhanbetova, Idiya Ostretsova, Nazira Kassenova, Dana Kazyakhmetova, Aziza Yeskendirova · Organics · 2026
Kandasamy Pavithra, R. Durga Priyadharshini, Vyshnavi Manickam · Journal of Molecular Structure · 2025
Aishwarya Dande, H. M. Chandra Mouli, Joshita Nandy · Critical Reviews in Analytical Chemistry · 2025
Torati Srinivas, K. V. N. Suresh Reddy, Sigilipalli Ramu · SEPARATION SCIENCE PLUS · 2024
Helmut Buschmann, Norbert Handler, Ulrike Holzgrabe · Journal of Pharmaceutical and Biomedical Analysis · 2024
Ilyoung Ahn, Yeongeun Jeong, Soyeon Lee · Microchemical Journal · 2026
Praveen Kumar Kondaveti, Paul Douglas Sanasi, G Saravanan · SEPARATION SCIENCE PLUS · 2024
Showing 7 of 23 known citations — external sources report more than can currently be individually listed.
Related research
- Taxonomy of the Rhizobia: Current Perspectives — shares topic coverage
- Mathematical Analysis of a Class of Surface-Tension Driven Flows — shares topic coverage
- Experiments on the Use of Machine Learning Classification Methods in Online Crime Text Filtering and Classification — shares topic coverage
- A Novel Approach to Predict the Performance of Student and Knowledge Discovery Based on Previous Record — shares topic coverage
- Community Based Study of Cerebrovascular Risk Factors in Tripoli-Libya (North Africa) — shares topic coverage
Article metrics
Real usage data collected on this platform.
86
Page views
0
PDF downloads
11
Outbound clicks
23
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.